SER קצב צמיחת רווח למניה בשנה הנוכחית Serina Therapeutics, Inc.

Serina Therapeutics, Inc. (SER) relies on its transparent POZ platform and authoritative scientific management. The eco-friendly synthesis of drugs in laboratories is complemented by stable operations within the US jurisdiction. The annual EPS growth rate demonstrates the dynamics of its cash generator, while 23.30 represents the latest metric reading, allowing for a real-time assessment of the issuer's current financial stability.
פילוחי מדדים מקיפים ואנליטיקה עבור Serina Pharma (SER)

This indicator calculates the annual growth of earnings per share, reflecting the rate of change in the company's net yield. During periods of market instability, the metric often enters consolidation, signaling uncertainty and the risk of false breakouts. For Serina Therapeutics, Inc. (SER), such fluctuations depend on the costs associated with the complex transportation of polymer compounds during the development of neurological drugs. The efficiency of these logistics directly impacts the bottom line. By analyzing the annual trajectory of earnings per share, an investor determines the fundamental stability of the business.